Kura Oncology (NASDAQ:KURA) Coverage Initiated by Analysts at UBS Group

Equities researchers at UBS Group began coverage on shares of Kura Oncology (NASDAQ:KURA) in a report issued on Thursday, MarketBeat reports. The firm set a “buy” rating and a $27.00 price target on the stock. UBS Group’s target price suggests a potential upside of 54.20% from the stock’s previous close.

KURA has been the subject of a number of other reports. Stifel Nicolaus lowered shares of Kura Oncology from a “buy” rating to a “hold” rating and lowered their price target for the company from $26.00 to $19.00 in a report on Monday, October 14th. HC Wainwright reiterated a “buy” rating and set a $32.00 price target on shares of Kura Oncology in a report on Monday, August 12th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Kura Oncology in a report on Monday, September 9th. JMP Securities reissued a “market outperform” rating and set a $32.00 price objective on shares of Kura Oncology in a research report on Monday, August 12th. Finally, Wedbush reissued an “outperform” rating and set a $37.00 price objective on shares of Kura Oncology in a research report on Friday, August 9th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $28.83.

Kura Oncology Trading Down 1.5 %

Shares of KURA opened at $17.51 on Thursday. The firm has a market cap of $1.34 billion, a price-to-earnings ratio of -7.85 and a beta of 0.84. The company has a debt-to-equity ratio of 0.02, a quick ratio of 14.94 and a current ratio of 14.94. Kura Oncology has a fifty-two week low of $7.52 and a fifty-two week high of $24.17. The firm has a 50 day moving average price of $19.34 and a 200-day moving average price of $20.09.

Kura Oncology (NASDAQ:KURA) last posted its quarterly earnings results on Thursday, August 8th. The company reported ($0.59) EPS for the quarter, beating analysts’ consensus estimates of ($0.63) by $0.04. During the same quarter in the prior year, the business earned ($0.53) EPS. The company’s quarterly revenue was up .0% compared to the same quarter last year. As a group, equities research analysts forecast that Kura Oncology will post -2.46 earnings per share for the current year.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the stock. China Universal Asset Management Co. Ltd. grew its position in shares of Kura Oncology by 64.7% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 14,739 shares of the company’s stock worth $288,000 after buying an additional 5,788 shares during the period. nVerses Capital LLC purchased a new stake in shares of Kura Oncology in the 3rd quarter worth about $25,000. Quarry LP purchased a new stake in shares of Kura Oncology in the 2nd quarter worth about $196,000. Alethea Capital Management LLC grew its position in shares of Kura Oncology by 2.4% in the 2nd quarter. Alethea Capital Management LLC now owns 265,906 shares of the company’s stock worth $5,475,000 after buying an additional 6,300 shares during the period. Finally, The Manufacturers Life Insurance Company grew its position in shares of Kura Oncology by 5.4% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 38,536 shares of the company’s stock worth $793,000 after buying an additional 1,976 shares during the period.

Kura Oncology Company Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.